Tag:
macitentan
Latest Headlines
Latest Headlines
Actelion surges as positive PhIII macitentan data reignites buyout buzz
The data signals to investors that the Swiss company can be ready for the loss of patent protection on its primary earner with the introduction of another blockbuster.
Swiss biotech Actelion grabs rights to biologic in $68.5M deal
With plans to beef up its limited commercial offerings, Swiss biotech Actelion ( $ATLN ) has secured rights in certain countries to Auxilium's ( $AUXL ) biotech drug for treating tissue buildups...
Actelion hunts for answers about 120 deaths in key drug trial
Actelion ( $ATLN ) CEO Jean-Paul Clozel has been clear about the importance of macitentan for the Swiss biotech's future in the blockbuster market for pulmonary arterial hypertension (PAH) drugs. So
Actelion braces for looming pivotal data on blockbuster macitentan program
Actelion's ( $ATLN ) approach to the year ahead might best be described as hoping for the best while preparing for the worst. Crucial late-stage data on macitentan is due to read out in the second
Actelion drug flunks PhII but safety data bolsters confidence in blockbuster PhIII
Typically, when a drug fails a mid-stage study and the biotech announces it will shelve the program as a result, it's counted as a black mark. But there isn't anything typical about Actelion's
Actelion hires Goldman, law firm to fend off Elliott Advisors
Actelion has hired Goldman Sachs in a move that indicates the Swiss biotech may eventually be sold to the right bidder. The company also retained the services of law firm Wachtell, Lipton, Rosen
